Professor | Yanling Wu | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Yanling Wu
Contact Information	yanlingwu@fudan.edu.cn
Language ability	Chinese, English
Province	Shanghai

Upload Avatar (500 x 500)

Name

Yanling Wu

Contact Information

yanlingwu@fudan.edu.cn

Language ability

Chinese, English

Province

Shanghai

University/Lab Affiliation and Title	Fudan University
Faculty	Basic Medical Sciences
Academic Background & Achievements	2008.09 – 2012.06 Bachelor's Degree (Biology): Liaoning Normal University 2012.09 – 2015.06 Master's Degree (Biology): Xinjiang University 2015.09 – 2018.06 Doctoral Degree (Basic Medicine): Fudan University
Work Experience	2018.06 – 2020.08 - Fudan University - Postdoctoral Researcher 2020.09 – Present - Fudan University - Associate Researcher 2021.01 – Present - Shanghai Synthetic Immunology Engineering Technology Research Center - Deputy Director
Awards	2018: Shanghai 'Super Postdoctoral Fellow', Shanghai Human Resources and Social Security Bureau 2018: Shanghai Outstanding Graduate, Shanghai Municipal Education Commission 2018: One Health Fund Award, One Health Fund 2017: Antibodies 2017 Award, Antibodies

University/Lab Affiliation and Title

Fudan University

Faculty

Basic Medical Sciences

Academic Background & Achievements

2008.09 – 2012.06 Bachelor's Degree (Biology): Liaoning Normal University
2012.09 – 2015.06 Master's Degree (Biology): Xinjiang University
2015.09 – 2018.06 Doctoral Degree (Basic Medicine): Fudan University

Work Experience

2018.06 – 2020.08 - Fudan University - Postdoctoral Researcher
2020.09 – Present - Fudan University - Associate Researcher
2021.01 – Present - Shanghai Synthetic Immunology Engineering Technology Research Center - Deputy Director

Awards

2018: Shanghai 'Super Postdoctoral Fellow', Shanghai Human Resources and Social Security Bureau
2018: Shanghai Outstanding Graduate, Shanghai Municipal Education Commission
2018: One Health Fund Award, One Health Fund
2017: Antibodies 2017 Award, Antibodies

Areas of Focus	Artificial modification and application of immune molecules Development and application of newly structured synthetic antibodies
Publications	Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody, Li, C., Zhan, W., Yang, Z., Tu, C., Hu, G., Zhang, X., Song, W., Du, S., Zhu, Y., Huang, K., Kong, Y., Zhang, M., Mao, Q., Gu, X., Zhang, Y., Xie, Y., Deng, Q., Song, Y., Chen, Z., Lu, L., Jiang, S., Wu, Y., Sun, L., Ying, T., 2022 Design of a Novel Fab-Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use, Wang, C., Hong, J., Yang, Z., Zhou, X., Yang, Y., Kong, Y., Chen, B., Wu, H., Qian, B. Z., Dimitrov, D. S., Zhou, X., Wu, Y., Ying, T., 2021 The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2, Li, C., Tian, X., Jia, X., Wan, J., Lu, L., Jiang, S., Lan, F., Lu, Y., Wu, Y., Ying, T., 2021 Identification of Human Single-Domain Antibodies against SARS-CoV-2, Wu, Y., Li, C., Xia, S., Tian, X., Kong, Y., Wang, Z., Gu, C., Zhang, R., Tu, C., Xie, Y., Yang, Z., Lu, L., Jiang, S., Ying, T., 2020 Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection, Wu, Y., Xue, J., Wang, C., Li, W., Wang, L., Chen, W., Prabakaran, P., Kong, D., Jin, Y., Hu, D., Wang, Y., Lei, C., Yu, D., Tu, C., Bardhi, A., Sidorov, I., Ma, L., Goldstein, H., Qin, C., Lu, L., Jiang, S., Dimitrov, D.S., Ying, T., 2019

Areas of Focus

Artificial modification and application of immune molecules
Development and application of newly structured synthetic antibodies

Publications

Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody, Li, C., Zhan, W., Yang, Z., Tu, C., Hu, G., Zhang, X., Song, W., Du, S., Zhu, Y., Huang, K., Kong, Y., Zhang, M., Mao, Q., Gu, X., Zhang, Y., Xie, Y., Deng, Q., Song, Y., Chen, Z., Lu, L., Jiang, S., Wu, Y., Sun, L., Ying, T., 2022
Design of a Novel Fab-Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use, Wang, C., Hong, J., Yang, Z., Zhou, X., Yang, Y., Kong, Y., Chen, B., Wu, H., Qian, B. Z., Dimitrov, D. S., Zhou, X., Wu, Y., Ying, T., 2021
The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2, Li, C., Tian, X., Jia, X., Wan, J., Lu, L., Jiang, S., Lan, F., Lu, Y., Wu, Y., Ying, T., 2021
Identification of Human Single-Domain Antibodies against SARS-CoV-2, Wu, Y., Li, C., Xia, S., Tian, X., Kong, Y., Wang, Z., Gu, C., Zhang, R., Tu, C., Xie, Y., Yang, Z., Lu, L., Jiang, S., Ying, T., 2020
Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection, Wu, Y., Xue, J., Wang, C., Li, W., Wang, L., Chen, W., Prabakaran, P., Kong, D., Jin, Y., Hu, D., Wang, Y., Lei, C., Yu, D., Tu, C., Bardhi, A., Sidorov, I., Ma, L., Goldstein, H., Qin, C., Lu, L., Jiang, S., Dimitrov, D.S., Ying, T., 2019

Immune Molecules Artificial Modification Application Directed Evolution Synthetic Tumor Infectious Diseases Treatment Antibodies Nanobodies

Xuefeng Niu - Guangzhou Medical University

Huang Bo - Peking Union Medical College

Li Bofeng - University of Science and Technology of China

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us